Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting Report

Evaluation of MH-PC-AB-53 peptideas a carcinoma therapeutic agent

Shih-Wei Lo, Ming-Hsin Li, Shih-Min Wang, Ming-Wei Chen and wei-lin lo
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 3114;
Shih-Wei Lo
1Institute of Nuclear Energy Research Taoyuan Taiwan
3Institute of Nuclear Energy Research Taoyuan Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Hsin Li
2Institute of Nuclear Energy Research Tauyuan City Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shih-Min Wang
1Institute of Nuclear Energy Research Taoyuan Taiwan
3Institute of Nuclear Energy Research Taoyuan Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Wei Chen
1Institute of Nuclear Energy Research Taoyuan Taiwan
3Institute of Nuclear Energy Research Taoyuan Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
wei-lin lo
1Institute of Nuclear Energy Research Taoyuan Taiwan
3Institute of Nuclear Energy Research Taoyuan Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

3114

Objectives: MH-PC-AB-53 showed high binding affinity for prostate-specific membrane antigen. Radiolabeled PSMA peptides that are prostate specific can be used for prostate -targeted radiotheragnostic application. The MH-PC-AB-53 (15-30μg) was labeled with ~3 or ~6mCi InCl3 (from INER) in sodium acetate (NaOAc) with different pH values (4.0-6.0) at 95℃ within 15mins. After labeling with In-111, quality control was performed by RP-HPLC and radio thin layer chromatography. Radiochemical purity was analyzed in the radio-TLC scanner with a 0.1M citric acid solution as the mobile phase. The Rf of free In-111 was approximately 0.95, and the Rf of 111In -MH-PC-AB-53 was approximately 0.05. The Radiochemical purity of the 111In-MH-PC-AB-53 was assayed by TLC(96.8%) and HPLC (96%). LNCaP tumor bearing mice were intravenously injected with 111In -MH-PC-AB-53. Scans were performed 1, 4, and 24 h after the administration. 111In-MH-PC-AB-53 showed high tumor uptake at all time points.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of MH-PC-AB-53 peptideas a carcinoma therapeutic agent
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Evaluation of MH-PC-AB-53 peptideas a carcinoma therapeutic agent
Shih-Wei Lo, Ming-Hsin Li, Shih-Min Wang, Ming-Wei Chen, wei-lin lo
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 3114;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of MH-PC-AB-53 peptideas a carcinoma therapeutic agent
Shih-Wei Lo, Ming-Hsin Li, Shih-Min Wang, Ming-Wei Chen, wei-lin lo
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 3114;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Rest Dose Spillover Correction of Stress Blood Flow Measurements in Digital Rb-82 Myocardial Perfusion PET/CT Imaging
  • Radiolabeled hyaluronic acid (HA) fragments for lymphatic imaging
  • Immunohistochemical validation and efficacy of 68Ga-Trivehexin PET CT as molecular imaging agent for αvβ6 integrin expression in patients of Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma.
Show more

Technologist Poster Session

  • Optimization of Standardized Uptake Value of Fluorodeoxyglucose for Cortical Extraction in dedicated brain PET System
  • Utilization of Gallium-68 Dotatate PET MRI for the Evaluation of Meningioma in a Major Tertiary Academic University Neurosurgical Center
  • Artificial Intelligence in Nuclear Medicine for Brain Imaging.
Show more Technologist Poster Session

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire